β-Blockers in heart failure: Benefits of β-blockers according to varying male proportions of study patients

Clinical Cardiology

Volumn 35, Issue 8, 2012, Pages 505-511

  He, Yong Ming ^a   Yang, Xiang Jun ^a   Zhao, Xin ^a   Cheng, Xu Jie ^a   Xu, Hai Feng ^a   Qian, Yun Xia ^a   Li, Xun ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BISOPROLOL; CARVEDILOL; METOPROLOL; PLACEBO;

ARTICLE; CAUSE OF DEATH; HEART DEATH; HEART FAILURE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTENTION TO TREAT ANALYSIS; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; SEX DIFFERENCE; SUDDEN DEATH; TREATMENT DURATION;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BISOPROLOL; CARBAZOLES; CHINA; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; METOPROLOL; PROPANOLAMINES; STATISTICS AS TOPIC; VASODILATOR AGENTS;

EID: 84864678466     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.21985     Document Type: Article

References (42)

1. Packer M., Pathophysiology of chronic heart failure. Lancet. 1992; 340: 88-92.
2. Brophy JM, Joseph L, Rouleau JL., Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med. 2001; 134: 550-560. (Pubitemid 32245316)
3. Jessup M, Abraham WT, Casey DE, et al. 2009. focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009; 119: 1977-2016
4. Bonet S, Agusti A, Arnau JM, et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients' characteristics: ameta-analysis of clinical trials. Arch Intern Med. 2000; 160: 621-627. (Pubitemid 30140411)
5. Doughty RN, Rodgers A, Sharpe N, et al. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Eur Heart J. 1997; 18: 560-565. (Pubitemid 27182346)
6. Heidenreich PA, Lee TT, Massie BM., Effect of beta-blockade on mortality in patients with heart failure: ameta-analysis of randomized clinical trials. J Am CollCardiol. 1997; 30: 27-34. (Pubitemid 27357123)
7. Lechat P, Packer M, Chalon S, et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: ameta-analysis of double-blind, placebo-controlled, randomized trials. Circulation. 1998; 98: 1184-1191. (Pubitemid 28436168)
8. Simon T, Mary-Krause M, Funck-Brentano C, et al. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation. 2001; 103: 375-380. (Pubitemid 32105976)
9. Ghali JK, Pina IL, Gottlieb SS, et al. Metoprolol cr/xl in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation. 2002; 105: 1585-1591. (Pubitemid 34297637)
10. Farasat SM, Bolger DT, Shetty V, et al. Effect of beta-blocker therapy on rehospitalization rates in women versus men with heart failure and preserved ejection fraction. Am J Cardiol. 2010; 105: 229-234.
11. Altman DG, Bland JM., Interaction revisited: the difference between two estimates. BMJ. 2003; 326: 219. (Pubitemid 36143396)
12. Engelmeier RS, O'Connell JB, Walsh R, et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: adouble-blind, randomized, placebo-controlled trial. Circulation. 1985; 72: 536-546. (Pubitemid 15242247)
13. Fisher ML, Gottlieb SS, Plotnick GD, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am CollCardiol. 1994; 23: 943-950. (Pubitemid 24090881)
14. Paolisso G, Gambardella A, Marrazzo G, et al. Metabolic and cardiovascular benefits deriving from beta-adrenergic blockade in chronic congestive heart failure. Am Heart J. 1992; 123: 103-110.
15. Anderson JL, Lutz JR, Gilbert EM, et al. A randomized trial of low-dosebeta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol. 1985; 55: 471-475. (Pubitemid 15173090)
16. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993; 342: 1441-1446. (Pubitemid 24000287)
17. Eichhorn EJ, Heesch CM, Barnett JH, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am CollCardiol. 1994; 24: 1310-1320. (Pubitemid 24331872)
18. Metra M, Nardi M, Giubbini R, et al. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am CollCardiol. 1994; 24: 1678-1687. (Pubitemid 24369193)
19. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. Circulation. 1995; 92: 212-218.
20. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995; 92: 1499-1506.
21. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: adouble-blind randomized study. J Am CollCardiol. 1995; 25: 1225-1231.
22. Krum H, Gu A, Wilshire-Clement M, et al. Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. Am Heart J. 1996; 131: 337-341. (Pubitemid 26043395)
23. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334: 1349-1355. (Pubitemid 26152713)
24. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353: 9-13.
25. Guazzi M, Agostoni P, Matturri M, et al. Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. Am Heart J. 1999; 138: 460-467. (Pubitemid 29428768)
26. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation. 2000; 101: 378-384.
27. Genth-Zotz S, Zotz RJ, Sigmund M, et al. MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing. Eur J Heart Fail. 2000; 2: 175-181. (Pubitemid 30407558)
28. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/Xl Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000; 283: 1295-1302. (Pubitemid 30129796)
29. Dargie HJ., Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001; 357: 1385-1390. (Pubitemid 32455364)
30. de Milliano PA, de Groot AC, Tijssen JG, et al. Beneficial effects of metoprolol on myocardial sympathetic function: evidence from a randomized, placebo-controlled study in patients with congestive heart failure. Am Heart J. 2002;144:E3.
31. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation. 2002; 106: 2194-2199. (Pubitemid 35222212)
32. Palazzuoli A, Bruni F, Puccetti L, et al. Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure. Eur J Heart Fail. 2002; 4: 765-770. (Pubitemid 35403086)
33. Cleland JG, Pennell DJ, Ray SG, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet. 2003; 362: 14-21. (Pubitemid 36840896)
34. Bergstrom A, Andersson B, Edner M, et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail. 2004; 6: 453-461. (Pubitemid 38746589)
35. Cohen Solal A, Jondeau G, Beauvais F, et al. Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure. Eur J Heart Fail. 2004; 6: 463-466. (Pubitemid 38746590)
36. De Matos LD, Gardenghi G, Rondon MU, et al. Impact of 6 months of therapy with carvedilol on muscle sympathetic nerve activity in heart failure patients. J Card Fail. 2004; 10: 496-502.
37. Hori M, Sasayama S, Kitabatake A, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J. 2004; 147: 324-330. (Pubitemid 38176834)
38. Gruner Svealv B, Tang MS, Waagstein F, et al. Pronounced improvement in systolic and diastolic ventricular long axis function after treatment with metoprolol. Eur J Heart Fail. 2007; 9: 678-683. (Pubitemid 46705569)
39. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CibisInvestigators and Committees. Circulation. 1994; 90: 1765-1773.
40. Klein L, Grau-Sepulveda MV, Bonow RO, et al. Quality of care and outcomes in women hospitalized for heart failure. Circ Heart Fail. 2011; 4: 589-598.
41. O'Connor CM, Fiuzat M, Swedberg K, et al. Influence of global region on outcomes in heart failure beta-blocker trials. J Am CollCardiol. 2011; 58: 915-922.
42. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003; 362: 7-13. (Pubitemid 36835815)